ProCE Banner Activity

Low-Dose Dasatinib vs Standard-Dose Dasatinib in Newly Diagnosed CP-CML: A Propensity Score Analysis

Slideset Download
Conference Coverage
In this analysis, comparable efficacy with better tolerance was reported for low-dose dasatinib vs standard-dose dasatinib in patients with newly diagnosed chronic-phase CML.

Released: December 21, 2021

Expiration: December 20, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation